Last updated on September 2015

Focal Segmental Glomerulosclerosis

Brief description of study

Focal Segmental Glomerulosclerosis

Detailed Study Description

In this study Retrophin is studying an investigational drug called Sparsentan for treatment of patients with FSGS. The trial is being conducted to collect information about the possible effects of Sparsentan to treat protein loss in patients with FSGS, as well as other positive and negative effects of the medication.

Clinical Study Identifier: TX141450

Find a site near you

Start Over

Northeast Clinical Research Center, LLC.

2014 City Line Rd.<br /> Suite 103 Bethlehem, PA USA
  Connect »